Ucb Sustainability Profile
UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ucb's score of 95 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ucb's reported carbon emissions
In 2024, UCB reported total greenhouse gas emissions of approximately 790,866,000 kg CO2e, with Scope 1 emissions at about 21,718,000 kg CO2e, Scope 2 emissions at approximately 5,000 kg CO2e (market-based), and a significant Scope 3 contribution of around 769,143,000 kg CO2e. This represents a decrease from 2023, where total emissions were about 853,320,000 kg CO2e. UCB has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 baseline, and to achieve a 90% reduction by 2045. For Scope 3 emissions, the company targets a 48% reduction by 2030 and a 90% reduction by 2045. Additionally, UCB is committed to ensuring that 80% of its suppliers by emissions will have science-based targets by 2028. These targets align with UCB's long-term goal of reaching net-zero emissions across its value chain by 2045, demonstrating a strong commitment to sustainability and climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,059,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 5,316,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000 |
| Scope 3 | 568,003,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 |
How Carbon Intensive is Ucb's Industry?
How Carbon Intensive is Ucb's Location?
Ucb's Scope 3 Categories Breakdown
Ucb's Scope 3 emissions, which increased significantly last year and increased by approximately 35% since 2015, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 90% of Scope 3 emissions.
Top Scope 3 Categories
Ucb's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ucb has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Ucb's sustainability data and climate commitments